Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Current Deferred Revenue (2016 - 2017)

Nephros (NEPH) has 8 years of Current Deferred Revenue data on record, last reported at $70000.0 in Q4 2017.

  • For Q4 2017, Current Deferred Revenue changed 0.0% year-over-year to $70000.0; the TTM value through Dec 2017 reached $70000.0, changed 0.0%, while the annual FY2017 figure was $70000.0, 0.0% changed from the prior year.
  • Current Deferred Revenue reached $70000.0 in Q4 2017 per NEPH's latest filing, roughly flat from $70000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $873000.0 in Q2 2014 and bottomed at $70000.0 in Q1 2015.
  • Average Current Deferred Revenue over 5 years is $306150.0, with a median of $157500.0 recorded in 2014.
  • Peak YoY movement for Current Deferred Revenue: tumbled 91.98% in 2015, then skyrocketed 447.14% in 2016.
  • A 5-year view of Current Deferred Revenue shows it stood at $703000.0 in 2013, then tumbled by 30.73% to $487000.0 in 2014, then tumbled by 85.63% to $70000.0 in 2015, then changed by 0.0% to $70000.0 in 2016, then changed by 0.0% to $70000.0 in 2017.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $70000.0 in Q4 2017, $70000.0 in Q3 2017, and $70000.0 in Q2 2017.